Global Amyotrophic Lateral Sclerosis (ALS) Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Amyotrophic Lateral Sclerosis (ALS) market size was valued at US$ 293.5 million in 2023. With growing demand in downstream market, the Amyotrophic Lateral Sclerosis (ALS) is forecast to a readjusted size of US$ 353.6 million by 2030 with a CAGR of 2.7% during review period.
The research report highlights the growth potential of the global Amyotrophic Lateral Sclerosis (ALS) market. Amyotrophic Lateral Sclerosis (ALS) are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Amyotrophic Lateral Sclerosis (ALS). Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Amyotrophic Lateral Sclerosis (ALS) market.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
Key Features:
The report on Amyotrophic Lateral Sclerosis (ALS) market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Amyotrophic Lateral Sclerosis (ALS) market. It may include historical data, market segmentation by Type (e.g., Riluzole, Edaravone (Radicava)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Amyotrophic Lateral Sclerosis (ALS) market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Amyotrophic Lateral Sclerosis (ALS) market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Amyotrophic Lateral Sclerosis (ALS) industry. This include advancements in Amyotrophic Lateral Sclerosis (ALS) technology, Amyotrophic Lateral Sclerosis (ALS) new entrants, Amyotrophic Lateral Sclerosis (ALS) new investment, and other innovations that are shaping the future of Amyotrophic Lateral Sclerosis (ALS).
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Amyotrophic Lateral Sclerosis (ALS) market. It includes factors influencing customer ' purchasing decisions, preferences for Amyotrophic Lateral Sclerosis (ALS) product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Amyotrophic Lateral Sclerosis (ALS) market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Amyotrophic Lateral Sclerosis (ALS) market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Amyotrophic Lateral Sclerosis (ALS) market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Amyotrophic Lateral Sclerosis (ALS) industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Amyotrophic Lateral Sclerosis (ALS) market.
Market Segmentation:
Amyotrophic Lateral Sclerosis (ALS) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Amyotrophic Lateral Sclerosis (ALS) market?
What factors are driving Amyotrophic Lateral Sclerosis (ALS) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Amyotrophic Lateral Sclerosis (ALS) market opportunities vary by end market size?
How does Amyotrophic Lateral Sclerosis (ALS) break out type, application?
According to our LPI (LP Information) latest study, the global Amyotrophic Lateral Sclerosis (ALS) market size was valued at US$ 293.5 million in 2023. With growing demand in downstream market, the Amyotrophic Lateral Sclerosis (ALS) is forecast to a readjusted size of US$ 353.6 million by 2030 with a CAGR of 2.7% during review period.
The research report highlights the growth potential of the global Amyotrophic Lateral Sclerosis (ALS) market. Amyotrophic Lateral Sclerosis (ALS) are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Amyotrophic Lateral Sclerosis (ALS). Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Amyotrophic Lateral Sclerosis (ALS) market.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
Key Features:
The report on Amyotrophic Lateral Sclerosis (ALS) market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Amyotrophic Lateral Sclerosis (ALS) market. It may include historical data, market segmentation by Type (e.g., Riluzole, Edaravone (Radicava)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Amyotrophic Lateral Sclerosis (ALS) market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Amyotrophic Lateral Sclerosis (ALS) market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Amyotrophic Lateral Sclerosis (ALS) industry. This include advancements in Amyotrophic Lateral Sclerosis (ALS) technology, Amyotrophic Lateral Sclerosis (ALS) new entrants, Amyotrophic Lateral Sclerosis (ALS) new investment, and other innovations that are shaping the future of Amyotrophic Lateral Sclerosis (ALS).
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Amyotrophic Lateral Sclerosis (ALS) market. It includes factors influencing customer ' purchasing decisions, preferences for Amyotrophic Lateral Sclerosis (ALS) product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Amyotrophic Lateral Sclerosis (ALS) market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Amyotrophic Lateral Sclerosis (ALS) market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Amyotrophic Lateral Sclerosis (ALS) market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Amyotrophic Lateral Sclerosis (ALS) industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Amyotrophic Lateral Sclerosis (ALS) market.
Market Segmentation:
Amyotrophic Lateral Sclerosis (ALS) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Riluzole
- Edaravone (Radicava)
- Other
- Hospital
- Drugs Store
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Mitsubishi Tanabe Pharma
- Sanofi
- Mylan Pharma
- Apotex
- Glemark Generics
- Covis Pharma
- Sun Pharma
- Lunan Pharma
What is the 10-year outlook for the global Amyotrophic Lateral Sclerosis (ALS) market?
What factors are driving Amyotrophic Lateral Sclerosis (ALS) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Amyotrophic Lateral Sclerosis (ALS) market opportunities vary by end market size?
How does Amyotrophic Lateral Sclerosis (ALS) break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Amyotrophic Lateral Sclerosis (ALS) by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Amyotrophic Lateral Sclerosis (ALS) by Country/Region, 2019, 2023 & 2030
2.2 Amyotrophic Lateral Sclerosis (ALS) Segment by Type
2.2.1 Riluzole
2.2.2 Edaravone (Radicava)
2.2.3 Other
2.3 Amyotrophic Lateral Sclerosis (ALS) Sales by Type
2.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
2.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue and Market Share by Type (2019-2024)
2.3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Type (2019-2024)
2.4 Amyotrophic Lateral Sclerosis (ALS) Segment by Application
2.4.1 Hospital
2.4.2 Drugs Store
2.4.3 Other
2.5 Amyotrophic Lateral Sclerosis (ALS) Sales by Application
2.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Sale Market Share by Application (2019-2024)
2.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue and Market Share by Application (2019-2024)
2.5.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Application (2019-2024)
3 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY COMPANY
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Breakdown Data by Company
3.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales by Company (2019-2024)
3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Company (2019-2024)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue by Company (2019-2024)
3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2019-2024)
3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company (2019-2024)
3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Company
3.4 Key Manufacturers Amyotrophic Lateral Sclerosis (ALS) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Amyotrophic Lateral Sclerosis (ALS) Product Location Distribution
3.4.2 Players Amyotrophic Lateral Sclerosis (ALS) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY GEOGRAPHIC REGION
4.1 World Historic Amyotrophic Lateral Sclerosis (ALS) Market Size by Geographic Region (2019-2024)
4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Amyotrophic Lateral Sclerosis (ALS) Market Size by Country/Region (2019-2024)
4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales by Country/Region (2019-2024)
4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue by Country/Region (2019-2024)
4.3 Americas Amyotrophic Lateral Sclerosis (ALS) Sales Growth
4.4 APAC Amyotrophic Lateral Sclerosis (ALS) Sales Growth
4.5 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Growth
4.6 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Growth
5 AMERICAS
5.1 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Country
5.1.1 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024)
5.1.2 Americas Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024)
5.2 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Type
5.3 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Region
6.1.1 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2019-2024)
6.1.2 APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2019-2024)
6.2 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Type
6.3 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Amyotrophic Lateral Sclerosis (ALS) by Country
7.1.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024)
7.1.2 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024)
7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type
7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) by Country
8.1.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024)
8.1.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024)
8.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Type
8.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Amyotrophic Lateral Sclerosis (ALS)
10.3 Manufacturing Process Analysis of Amyotrophic Lateral Sclerosis (ALS)
10.4 Industry Chain Structure of Amyotrophic Lateral Sclerosis (ALS)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
11.3 Amyotrophic Lateral Sclerosis (ALS) Customer
12 WORLD FORECAST REVIEW FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY GEOGRAPHIC REGION
12.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Region
12.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Region (2025-2030)
12.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Type
12.7 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Mitsubishi Tanabe Pharma
13.1.1 Mitsubishi Tanabe Pharma Company Information
13.1.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Mitsubishi Tanabe Pharma Main Business Overview
13.1.5 Mitsubishi Tanabe Pharma Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Mylan Pharma
13.3.1 Mylan Pharma Company Information
13.3.2 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Mylan Pharma Main Business Overview
13.3.5 Mylan Pharma Latest Developments
13.4 Apotex
13.4.1 Apotex Company Information
13.4.2 Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Apotex Main Business Overview
13.4.5 Apotex Latest Developments
13.5 Glemark Generics
13.5.1 Glemark Generics Company Information
13.5.2 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Glemark Generics Main Business Overview
13.5.5 Glemark Generics Latest Developments
13.6 Covis Pharma
13.6.1 Covis Pharma Company Information
13.6.2 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Covis Pharma Main Business Overview
13.6.5 Covis Pharma Latest Developments
13.7 Sun Pharma
13.7.1 Sun Pharma Company Information
13.7.2 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Sun Pharma Main Business Overview
13.7.5 Sun Pharma Latest Developments
13.8 Lunan Pharma
13.8.1 Lunan Pharma Company Information
13.8.2 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Lunan Pharma Main Business Overview
13.8.5 Lunan Pharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Amyotrophic Lateral Sclerosis (ALS) by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Amyotrophic Lateral Sclerosis (ALS) by Country/Region, 2019, 2023 & 2030
2.2 Amyotrophic Lateral Sclerosis (ALS) Segment by Type
2.2.1 Riluzole
2.2.2 Edaravone (Radicava)
2.2.3 Other
2.3 Amyotrophic Lateral Sclerosis (ALS) Sales by Type
2.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
2.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue and Market Share by Type (2019-2024)
2.3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Type (2019-2024)
2.4 Amyotrophic Lateral Sclerosis (ALS) Segment by Application
2.4.1 Hospital
2.4.2 Drugs Store
2.4.3 Other
2.5 Amyotrophic Lateral Sclerosis (ALS) Sales by Application
2.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Sale Market Share by Application (2019-2024)
2.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue and Market Share by Application (2019-2024)
2.5.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Application (2019-2024)
3 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY COMPANY
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Breakdown Data by Company
3.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales by Company (2019-2024)
3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Company (2019-2024)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue by Company (2019-2024)
3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2019-2024)
3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company (2019-2024)
3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Company
3.4 Key Manufacturers Amyotrophic Lateral Sclerosis (ALS) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Amyotrophic Lateral Sclerosis (ALS) Product Location Distribution
3.4.2 Players Amyotrophic Lateral Sclerosis (ALS) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY GEOGRAPHIC REGION
4.1 World Historic Amyotrophic Lateral Sclerosis (ALS) Market Size by Geographic Region (2019-2024)
4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Amyotrophic Lateral Sclerosis (ALS) Market Size by Country/Region (2019-2024)
4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales by Country/Region (2019-2024)
4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue by Country/Region (2019-2024)
4.3 Americas Amyotrophic Lateral Sclerosis (ALS) Sales Growth
4.4 APAC Amyotrophic Lateral Sclerosis (ALS) Sales Growth
4.5 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Growth
4.6 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Growth
5 AMERICAS
5.1 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Country
5.1.1 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024)
5.1.2 Americas Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024)
5.2 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Type
5.3 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Region
6.1.1 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2019-2024)
6.1.2 APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2019-2024)
6.2 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Type
6.3 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Amyotrophic Lateral Sclerosis (ALS) by Country
7.1.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024)
7.1.2 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024)
7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type
7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) by Country
8.1.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024)
8.1.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024)
8.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Type
8.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Amyotrophic Lateral Sclerosis (ALS)
10.3 Manufacturing Process Analysis of Amyotrophic Lateral Sclerosis (ALS)
10.4 Industry Chain Structure of Amyotrophic Lateral Sclerosis (ALS)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
11.3 Amyotrophic Lateral Sclerosis (ALS) Customer
12 WORLD FORECAST REVIEW FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY GEOGRAPHIC REGION
12.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Region
12.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Region (2025-2030)
12.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Type
12.7 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Mitsubishi Tanabe Pharma
13.1.1 Mitsubishi Tanabe Pharma Company Information
13.1.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Mitsubishi Tanabe Pharma Main Business Overview
13.1.5 Mitsubishi Tanabe Pharma Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Mylan Pharma
13.3.1 Mylan Pharma Company Information
13.3.2 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Mylan Pharma Main Business Overview
13.3.5 Mylan Pharma Latest Developments
13.4 Apotex
13.4.1 Apotex Company Information
13.4.2 Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Apotex Main Business Overview
13.4.5 Apotex Latest Developments
13.5 Glemark Generics
13.5.1 Glemark Generics Company Information
13.5.2 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Glemark Generics Main Business Overview
13.5.5 Glemark Generics Latest Developments
13.6 Covis Pharma
13.6.1 Covis Pharma Company Information
13.6.2 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Covis Pharma Main Business Overview
13.6.5 Covis Pharma Latest Developments
13.7 Sun Pharma
13.7.1 Sun Pharma Company Information
13.7.2 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Sun Pharma Main Business Overview
13.7.5 Sun Pharma Latest Developments
13.8 Lunan Pharma
13.8.1 Lunan Pharma Company Information
13.8.2 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Lunan Pharma Main Business Overview
13.8.5 Lunan Pharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Amyotrophic Lateral Sclerosis (ALS) Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Amyotrophic Lateral Sclerosis (ALS) Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Riluzole
Table 4. Major Players of Edaravone (Radicava)
Table 5. Major Players of Other
Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2024) & (K Unit)
Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2019-2024) & ($ million)
Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2019-2024)
Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Type (2019-2024) & (USD/Unit)
Table 11. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2024) & (K Unit)
Table 12. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2024)
Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2019-2024)
Table 14. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2019-2024)
Table 15. Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Application (2019-2024) & (USD/Unit)
Table 16. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Company (2019-2024) & (K Unit)
Table 17. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Company (2019-2024)
Table 18. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2019-2024) ($ Millions)
Table 19. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company (2019-2024)
Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Company (2019-2024) & (USD/Unit)
Table 21. Key Manufacturers Amyotrophic Lateral Sclerosis (ALS) Producing Area Distribution and Sales Area
Table 22. Players Amyotrophic Lateral Sclerosis (ALS) Products Offered
Table 23. Amyotrophic Lateral Sclerosis (ALS) Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Geographic Region (2019-2024) & (K Unit)
Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Geographic Region (2019-2024)
Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Country/Region (2019-2024) & (K Unit)
Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country/Region (2019-2024)
Table 32. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024) & (K Unit)
Table 35. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2019-2024)
Table 36. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024) & ($ Millions)
Table 37. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2019-2024)
Table 38. Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2024) & (K Unit)
Table 39. Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2024) & (K Unit)
Table 40. APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2019-2024) & (K Unit)
Table 41. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2019-2024)
Table 42. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2019-2024) & ($ Millions)
Table 43. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2019-2024)
Table 44. APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2024) & (K Unit)
Table 45. APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2024) & (K Unit)
Table 46. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024) & (K Unit)
Table 47. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2019-2024)
Table 48. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024) & ($ Millions)
Table 49. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2019-2024)
Table 50. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2024) & (K Unit)
Table 51. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2024) & (K Unit)
Table 52. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024) & (K Unit)
Table 53. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2019-2024)
Table 54. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024) & ($ Millions)
Table 55. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2019-2024)
Table 56. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2024) & (K Unit)
Table 57. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2024) & (K Unit)
Table 58. Key Market Drivers & Growth Opportunities of Amyotrophic Lateral Sclerosis (ALS)
Table 59. Key Market Challenges & Risks of Amyotrophic Lateral Sclerosis (ALS)
Table 60. Key Industry Trends of Amyotrophic Lateral Sclerosis (ALS)
Table 61. Amyotrophic Lateral Sclerosis (ALS) Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Amyotrophic Lateral Sclerosis (ALS) Distributors List
Table 64. Amyotrophic Lateral Sclerosis (ALS) Customer List
Table 65. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Region (2025-2030) & (K Unit)
Table 66. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2025-2030) & (K Unit)
Table 68. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Region (2025-2030) & (K Unit)
Table 70. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2025-2030) & (K Unit)
Table 72. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2025-2030) & (K Unit)
Table 74. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Type (2025-2030) & (K Unit)
Table 76. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 77. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Application (2025-2030) & (K Unit)
Table 78. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 79. Mitsubishi Tanabe Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 80. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 81. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 82. Mitsubishi Tanabe Pharma Main Business
Table 83. Mitsubishi Tanabe Pharma Latest Developments
Table 84. Sanofi Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 85. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 86. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 87. Sanofi Main Business
Table 88. Sanofi Latest Developments
Table 89. Mylan Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 90. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 91. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 92. Mylan Pharma Main Business
Table 93. Mylan Pharma Latest Developments
Table 94. Apotex Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 95. Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 96. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 97. Apotex Main Business
Table 98. Apotex Latest Developments
Table 99. Glemark Generics Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 100. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 101. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 102. Glemark Generics Main Business
Table 103. Glemark Generics Latest Developments
Table 104. Covis Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 105. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 106. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 107. Covis Pharma Main Business
Table 108. Covis Pharma Latest Developments
Table 109. Sun Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 110. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 111. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 112. Sun Pharma Main Business
Table 113. Sun Pharma Latest Developments
Table 114. Lunan Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 115. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 116. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 117. Lunan Pharma Main Business
Table 118. Lunan Pharma Latest Developments
Table 1. Amyotrophic Lateral Sclerosis (ALS) Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Amyotrophic Lateral Sclerosis (ALS) Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Riluzole
Table 4. Major Players of Edaravone (Radicava)
Table 5. Major Players of Other
Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2024) & (K Unit)
Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2019-2024) & ($ million)
Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2019-2024)
Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Type (2019-2024) & (USD/Unit)
Table 11. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2024) & (K Unit)
Table 12. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2024)
Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2019-2024)
Table 14. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2019-2024)
Table 15. Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Application (2019-2024) & (USD/Unit)
Table 16. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Company (2019-2024) & (K Unit)
Table 17. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Company (2019-2024)
Table 18. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2019-2024) ($ Millions)
Table 19. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company (2019-2024)
Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Company (2019-2024) & (USD/Unit)
Table 21. Key Manufacturers Amyotrophic Lateral Sclerosis (ALS) Producing Area Distribution and Sales Area
Table 22. Players Amyotrophic Lateral Sclerosis (ALS) Products Offered
Table 23. Amyotrophic Lateral Sclerosis (ALS) Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Geographic Region (2019-2024) & (K Unit)
Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Geographic Region (2019-2024)
Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Country/Region (2019-2024) & (K Unit)
Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country/Region (2019-2024)
Table 32. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024) & (K Unit)
Table 35. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2019-2024)
Table 36. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024) & ($ Millions)
Table 37. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2019-2024)
Table 38. Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2024) & (K Unit)
Table 39. Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2024) & (K Unit)
Table 40. APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2019-2024) & (K Unit)
Table 41. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2019-2024)
Table 42. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2019-2024) & ($ Millions)
Table 43. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2019-2024)
Table 44. APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2024) & (K Unit)
Table 45. APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2024) & (K Unit)
Table 46. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024) & (K Unit)
Table 47. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2019-2024)
Table 48. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024) & ($ Millions)
Table 49. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2019-2024)
Table 50. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2024) & (K Unit)
Table 51. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2024) & (K Unit)
Table 52. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024) & (K Unit)
Table 53. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2019-2024)
Table 54. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024) & ($ Millions)
Table 55. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2019-2024)
Table 56. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2024) & (K Unit)
Table 57. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2024) & (K Unit)
Table 58. Key Market Drivers & Growth Opportunities of Amyotrophic Lateral Sclerosis (ALS)
Table 59. Key Market Challenges & Risks of Amyotrophic Lateral Sclerosis (ALS)
Table 60. Key Industry Trends of Amyotrophic Lateral Sclerosis (ALS)
Table 61. Amyotrophic Lateral Sclerosis (ALS) Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Amyotrophic Lateral Sclerosis (ALS) Distributors List
Table 64. Amyotrophic Lateral Sclerosis (ALS) Customer List
Table 65. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Region (2025-2030) & (K Unit)
Table 66. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2025-2030) & (K Unit)
Table 68. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Region (2025-2030) & (K Unit)
Table 70. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2025-2030) & (K Unit)
Table 72. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2025-2030) & (K Unit)
Table 74. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Type (2025-2030) & (K Unit)
Table 76. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 77. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Application (2025-2030) & (K Unit)
Table 78. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 79. Mitsubishi Tanabe Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 80. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 81. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 82. Mitsubishi Tanabe Pharma Main Business
Table 83. Mitsubishi Tanabe Pharma Latest Developments
Table 84. Sanofi Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 85. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 86. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 87. Sanofi Main Business
Table 88. Sanofi Latest Developments
Table 89. Mylan Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 90. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 91. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 92. Mylan Pharma Main Business
Table 93. Mylan Pharma Latest Developments
Table 94. Apotex Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 95. Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 96. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 97. Apotex Main Business
Table 98. Apotex Latest Developments
Table 99. Glemark Generics Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 100. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 101. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 102. Glemark Generics Main Business
Table 103. Glemark Generics Latest Developments
Table 104. Covis Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 105. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 106. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 107. Covis Pharma Main Business
Table 108. Covis Pharma Latest Developments
Table 109. Sun Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 110. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 111. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 112. Sun Pharma Main Business
Table 113. Sun Pharma Latest Developments
Table 114. Lunan Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 115. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 116. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 117. Lunan Pharma Main Business
Table 118. Lunan Pharma Latest Developments
LIST OF FIGURES
Figure 1. Picture of Amyotrophic Lateral Sclerosis (ALS)
Figure 2. Amyotrophic Lateral Sclerosis (ALS) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate 2019-2030 (K Unit)
Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Riluzole
Figure 10. Product Picture of Edaravone (Radicava)
Figure 11. Product Picture of Other
Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type in 2023
Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2019-2024)
Figure 14. Amyotrophic Lateral Sclerosis (ALS) Consumed in Hospital
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Market: Hospital (2019-2024) & (K Unit)
Figure 16. Amyotrophic Lateral Sclerosis (ALS) Consumed in Drugs Store
Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Market: Drugs Store (2019-2024) & (K Unit)
Figure 18. Amyotrophic Lateral Sclerosis (ALS) Consumed in Other
Figure 19. Global Amyotrophic Lateral Sclerosis (ALS) Market: Other (2019-2024) & (K Unit)
Figure 20. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2023)
Figure 21. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application in 2023
Figure 22. Amyotrophic Lateral Sclerosis (ALS) Sales Market by Company in 2023 (K Unit)
Figure 23. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Company in 2023
Figure 24. Amyotrophic Lateral Sclerosis (ALS) Revenue Market by Company in 2023 ($ Million)
Figure 25. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company in 2023
Figure 26. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Geographic Region (2019-2024)
Figure 27. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Geographic Region in 2023
Figure 28. Americas Amyotrophic Lateral Sclerosis (ALS) Sales 2019-2024 (K Unit)
Figure 29. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue 2019-2024 ($ Millions)
Figure 30. APAC Amyotrophic Lateral Sclerosis (ALS) Sales 2019-2024 (K Unit)
Figure 31. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue 2019-2024 ($ Millions)
Figure 32. Europe Amyotrophic Lateral Sclerosis (ALS) Sales 2019-2024 (K Unit)
Figure 33. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue 2019-2024 ($ Millions)
Figure 34. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales 2019-2024 (K Unit)
Figure 35. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue 2019-2024 ($ Millions)
Figure 36. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country in 2023
Figure 37. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country in 2023
Figure 38. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
Figure 39. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2024)
Figure 40. United States Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 41. Canada Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 42. Mexico Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 43. Brazil Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 44. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region in 2023
Figure 45. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Regions in 2023
Figure 46. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
Figure 47. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2024)
Figure 48. China Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 49. Japan Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 50. South Korea Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 51. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 52. India Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 53. Australia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 54. China Taiwan Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 55. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country in 2023
Figure 56. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country in 2023
Figure 57. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
Figure 58. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2024)
Figure 59. Germany Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 60. France Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 61. UK Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 62. Italy Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 63. Russia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 64. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country in 2023
Figure 65. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country in 2023
Figure 66. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
Figure 67. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2024)
Figure 68. Egypt Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 69. South Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 70. Israel Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 71. Turkey Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 72. GCC Country Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Amyotrophic Lateral Sclerosis (ALS) in 2023
Figure 74. Manufacturing Process Analysis of Amyotrophic Lateral Sclerosis (ALS)
Figure 75. Industry Chain Structure of Amyotrophic Lateral Sclerosis (ALS)
Figure 76. Channels of Distribution
Figure 77. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Forecast by Region (2025-2030)
Figure 78. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share Forecast by Region (2025-2030)
Figure 79. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Type (2025-2030)
Figure 80. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share Forecast by Type (2025-2030)
Figure 81. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Application (2025-2030)
Figure 82. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Amyotrophic Lateral Sclerosis (ALS)
Figure 2. Amyotrophic Lateral Sclerosis (ALS) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate 2019-2030 (K Unit)
Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Riluzole
Figure 10. Product Picture of Edaravone (Radicava)
Figure 11. Product Picture of Other
Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type in 2023
Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2019-2024)
Figure 14. Amyotrophic Lateral Sclerosis (ALS) Consumed in Hospital
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Market: Hospital (2019-2024) & (K Unit)
Figure 16. Amyotrophic Lateral Sclerosis (ALS) Consumed in Drugs Store
Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Market: Drugs Store (2019-2024) & (K Unit)
Figure 18. Amyotrophic Lateral Sclerosis (ALS) Consumed in Other
Figure 19. Global Amyotrophic Lateral Sclerosis (ALS) Market: Other (2019-2024) & (K Unit)
Figure 20. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2023)
Figure 21. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application in 2023
Figure 22. Amyotrophic Lateral Sclerosis (ALS) Sales Market by Company in 2023 (K Unit)
Figure 23. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Company in 2023
Figure 24. Amyotrophic Lateral Sclerosis (ALS) Revenue Market by Company in 2023 ($ Million)
Figure 25. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company in 2023
Figure 26. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Geographic Region (2019-2024)
Figure 27. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Geographic Region in 2023
Figure 28. Americas Amyotrophic Lateral Sclerosis (ALS) Sales 2019-2024 (K Unit)
Figure 29. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue 2019-2024 ($ Millions)
Figure 30. APAC Amyotrophic Lateral Sclerosis (ALS) Sales 2019-2024 (K Unit)
Figure 31. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue 2019-2024 ($ Millions)
Figure 32. Europe Amyotrophic Lateral Sclerosis (ALS) Sales 2019-2024 (K Unit)
Figure 33. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue 2019-2024 ($ Millions)
Figure 34. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales 2019-2024 (K Unit)
Figure 35. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue 2019-2024 ($ Millions)
Figure 36. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country in 2023
Figure 37. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country in 2023
Figure 38. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
Figure 39. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2024)
Figure 40. United States Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 41. Canada Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 42. Mexico Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 43. Brazil Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 44. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region in 2023
Figure 45. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Regions in 2023
Figure 46. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
Figure 47. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2024)
Figure 48. China Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 49. Japan Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 50. South Korea Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 51. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 52. India Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 53. Australia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 54. China Taiwan Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 55. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country in 2023
Figure 56. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country in 2023
Figure 57. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
Figure 58. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2024)
Figure 59. Germany Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 60. France Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 61. UK Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 62. Italy Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 63. Russia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 64. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country in 2023
Figure 65. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country in 2023
Figure 66. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
Figure 67. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2024)
Figure 68. Egypt Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 69. South Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 70. Israel Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 71. Turkey Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 72. GCC Country Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2019-2024 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Amyotrophic Lateral Sclerosis (ALS) in 2023
Figure 74. Manufacturing Process Analysis of Amyotrophic Lateral Sclerosis (ALS)
Figure 75. Industry Chain Structure of Amyotrophic Lateral Sclerosis (ALS)
Figure 76. Channels of Distribution
Figure 77. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Forecast by Region (2025-2030)
Figure 78. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share Forecast by Region (2025-2030)
Figure 79. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Type (2025-2030)
Figure 80. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share Forecast by Type (2025-2030)
Figure 81. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Application (2025-2030)
Figure 82. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share Forecast by Application (2025-2030)
